Gene Panel Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2031F

The Gene Panel Market was valued at USD 2.98 Billion in 2024, and is expected to reach USD 4.55 Billion by 2030, rising at a CAGR of 7.45%. The global gene panel market is witnessing robust expansion, driven by the growing importance of genetic testing in the early diagnosis and treatment of various diseases. Gene panels, which allow simultaneous analysis of multiple genes, have become a cornerstone in the fields of oncology, rare disease detection, and pharmacogenomics. The shift toward personalized medicine and targeted therapies has significantly boosted the adoption of gene panel testing, especially for hereditary cancer risk assessment, congenital disorders, and neurological diseases.

Technological advancements in next-generation sequencing (NGS) have been pivotal in this growth, enabling faster, more accurate, and cost-effective analysis of gene variants. Amplicon-based and hybrid-capture based techniques have made it easier for researchers and clinicians to customize gene panels according to specific clinical requirements. For instance, in October 2023, China’s National Medical Products Administration (NMPA) approved Geneseeq’s tumor mutational burden test kit for non-small cell lung cancer (NSCLC). The kit features a comprehensive gene panel covering 425 cancer-related genes, aiming to enhance precision oncology by supporting more accurate diagnosis and treatment planning in lung cancer patients.

The decreasing cost of sequencing technologies and growing awareness among patients and healthcare providers are accelerating the market penetration of gene panels across both developed and emerging economies. Healthcare systems around the world are increasingly incorporating genetic information into clinical workflows, particularly for cancer diagnostics. Multigene panels are now frequently used to guide treatment decisions in breast, colorectal, and ovarian cancers. Beyond oncology, gene panels are also gaining traction in cardiology, infectious diseases, and prenatal testing, widening their scope of applications.

Key Market Drivers

Rising Incidence of Genetic and Chronic Diseases

The rising incidence of genetic and chronic diseases is a major driver propelling the growth of the global gene panel market. For instance, according to the Genetic and Rare Disease (GARD) Information Center, over 7,000 genetic conditions have been identified, with the number steadily increasing. In the U.S., at least 200,000 individuals live with known genetic disorders, while in the U.K., around 30,000 infants are diagnosed annually, contributing to over 2.4 million survivors. Gene panels are often developed to detect such conditions at birth, enabling timely diagnosis and early intervention through appropriate treatment and management strategies.

This early detection plays a crucial role in improving patient outcomes and reducing the long-term burden of genetic diseases. Over the past decade, there has been a significant increase in the prevalence of genetic disorders such as cystic fibrosis, thalassemia, and sickle cell anemia, as well as complex chronic conditions like cancer, cardiovascular diseases, and neurodegenerative disorders. Many of these diseases have a strong genetic component, making early and accurate detection through gene panels a critical aspect of modern diagnostics. Gene panels allow clinicians to analyze multiple genes simultaneously to identify mutations associated with hereditary conditions, enabling timely intervention and better disease management.

Cancer, in particular, has seen an alarming rise worldwide, with a growing emphasis on personalized treatment approaches based on individual genetic profiles. Gene panel testing has become an essential tool in oncology, helping to detect germline and somatic mutations that influence cancer susceptibility and treatment response. For instance, BRCA1 and BRCA2 gene panels are widely used to assess the risk of breast and ovarian cancers, guiding both preventive strategies and therapeutic choices. Similarly, chronic illnesses such as diabetes, Alzheimer's disease, and cardiovascular disorders often have underlying genetic factors that can be identified through targeted panels, allowing for more precise risk stratification and personalized care plans.

Key Market Challenges

High Cost of Testing and Equipment

The high cost of advanced filtration systems presents a significant challenge to the global gene panel market. As laboratories increasingly demand high-performance solutions for applications in pharmaceuticals, biotechnology, environmental testing, and academic research, the complexity and technological sophistication of filtration equipment have grown. However, this advancement comes at a cost - systems such as nanofiltration, ultrafiltration, and automated filtration setups require substantial capital investment. For many small- to medium-sized laboratories, especially in developing regions, these costs can be prohibitive.

Beyond initial acquisition, ongoing operational expenses further burden end users. Advanced filtration systems often require specialized membranes, maintenance kits, calibration, and sometimes custom configurations to suit specific applications. The need for compatibility with other lab infrastructure or integration into automated workflows can increase the total cost of ownership. In sectors where funding is limited or subject to fluctuations, such as academic or public health labs, high-cost systems may be considered an unjustifiable expenditure, leading to reliance on outdated or less efficient alternatives.

Key Market Trends

Integration of Artificial Intelligence and Machine Learning

The integration of Artificial Intelligence (AI) and Machine Learning (ML) into the global gene panel market is rapidly transforming the landscape of genetic testing and precision medicine. AI and ML technologies enhance the ability to analyze vast amounts of genomic data quickly and accurately, addressing one of the key challenges in gene panel testing - interpreting complex genetic variations and identifying clinically relevant mutations. By leveraging sophisticated algorithms, AI can detect subtle patterns and correlations within genetic datasets that may be missed by traditional methods, leading to improved diagnostic accuracy and personalized treatment recommendations.

In gene panel testing, AI-driven tools are increasingly used for variant classification, predicting pathogenicity, and prioritizing genetic mutations for clinical relevance. Machine learning models trained on large genomic databases help in distinguishing benign variants from those linked to disease, reducing the number of variants of unknown significance (VUS) and enhancing the clinical utility of gene panels. This capability is particularly valuable in oncology, where identifying actionable mutations can guide targeted therapies and immunotherapies, improving patient outcomes.

AI and ML enable automation of data processing pipelines, decreasing turnaround times and operational costs, which makes gene panel testing more accessible and scalable. The combination of AI with next-generation sequencing (NGS) platforms has led to the development of comprehensive cancer profiling assays that integrate genomic and epigenomic data, providing a more holistic view of tumor biology. For example, companies like Guardant Health use AI-powered liquid biopsy tests that non-invasively profile cancer-related genetic changes from blood samples, demonstrating the potential for less invasive and more frequent monitoring.

Key Market Players

• Illumina, Inc.
• Agilent Technologies, Inc.
• Thermo Fischer Scientific, Inc.
• QIAGEN NV
• Eurofins Scientific SE
• Foundation Medicine Inc.
• Guardant Health, Inc.
• Myriad Genetic Laboratories Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG

Report Scope:

In this report, the Global Gene Panel Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Gene Panel Market, By Component:

• Test Kits
• Testing Services

Gene Panel Market, By Technique:

• Amplicon Based Approach
• Hybridization Based Approach

Gene Panel Market, By End User:

• Academic & Research Institute
• Hospital & Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies

Gene Panel Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Gene Panel Market.

Available Customizations:

Global Gene Panel Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

• Detailed analysis and profiling of additional Market players (up to five).

This product will be delivered within 1-3 business days.